PE20071063A1 - Formulaciones de proteinas estables - Google Patents
Formulaciones de proteinas establesInfo
- Publication number
- PE20071063A1 PE20071063A1 PE2006001649A PE2006001649A PE20071063A1 PE 20071063 A1 PE20071063 A1 PE 20071063A1 PE 2006001649 A PE2006001649 A PE 2006001649A PE 2006001649 A PE2006001649 A PE 2006001649A PE 20071063 A1 PE20071063 A1 PE 20071063A1
- Authority
- PE
- Peru
- Prior art keywords
- sugar
- protein formulations
- stable protein
- formulation
- ctla4ig
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
REFERIDA A UNA FORMULACION ESTABLE QUE COMPRENDE AL MENOS 100 MG/ML DE MOLECULAS DE CTLA4Ig, UN AZUCAR TAL COMO SUCROSA, MALTOSA, LACTOSA, MANITOL, ENTRE OTRAS, Y UN PORTADOR ACUOSO FARMACEUTICAMENTE ACEPTABLE. LA MOLECULA CTLA4Ig TIENE LA SECUENCIA DE AMINOACIDOS MOSTRADA EN LA SEQ ID NO:2 COMENZANDO CON METIONINA EN LA POSICION 27 O ALANINA EN LA POSICION 26 Y TERMINANDO EN LA LISINA EN LA POSICION 383 O GLICINA EN LA POSICION 382. DICHA FORMULACION TIENE UNA PROPORCION DE PROTEINA Y AZUCAR DE 1:1.3 Y TIENE UN pH ENTRE 6 Y 8. LA FORMULACION PUEDE SER LIOFILIZADA O LIQUIDA Y SE PUEDE ADMINISTRAR VIA INTRAVENOSA O SUBCUTANEA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75215005P | 2005-12-20 | 2005-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20071063A1 true PE20071063A1 (es) | 2007-10-24 |
Family
ID=38057529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006001649A PE20071063A1 (es) | 2005-12-20 | 2006-12-19 | Formulaciones de proteinas estables |
Country Status (25)
Country | Link |
---|---|
US (1) | US8476239B2 (es) |
EP (1) | EP1962886B2 (es) |
JP (2) | JP5247467B2 (es) |
KR (1) | KR101378194B1 (es) |
CN (3) | CN101822820A (es) |
AR (2) | AR058567A1 (es) |
AU (1) | AU2006330593B2 (es) |
BR (1) | BRPI0622256A2 (es) |
CA (1) | CA2634547C (es) |
CL (1) | CL2010000816A1 (es) |
DK (1) | DK1962886T4 (es) |
EA (1) | EA014232B1 (es) |
ES (1) | ES2436616T5 (es) |
HK (1) | HK1114568A1 (es) |
HR (1) | HRP20131196T4 (es) |
IL (1) | IL192104A (es) |
NO (1) | NO347247B1 (es) |
NZ (1) | NZ569108A (es) |
PE (1) | PE20071063A1 (es) |
PL (1) | PL1962886T6 (es) |
PT (1) | PT1962886E (es) |
RS (1) | RS53127B2 (es) |
SG (1) | SG153832A1 (es) |
TW (3) | TW201008595A (es) |
WO (1) | WO2007076354A2 (es) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2253644T3 (pl) | 2005-12-20 | 2014-04-30 | Bristol Myers Squibb Co | Kompozycje i sposoby wytwarzania kompozycji |
AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
CN101822820A (zh) * | 2005-12-20 | 2010-09-08 | 布里斯托尔—迈尔斯斯奎布公司 | 稳定蛋白质制剂 |
US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
US7915222B2 (en) | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
BRPI0920030B1 (pt) | 2008-10-06 | 2019-03-26 | 3-D Matrix, Ltd. | Agente de oclusão do tecido, agentes hemostáticos, preventivos e de oclusão ou escleroterapia relacionados, e infusão do tecido mucosal |
CN102458621B (zh) * | 2009-06-23 | 2015-07-22 | 通用电气健康护理生物科学股份公司 | 模拟器装置 |
GB201009676D0 (en) * | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
JP5847418B2 (ja) | 2011-03-30 | 2016-01-20 | 富士フイルム株式会社 | 細胞接着性タンパク質 |
EP2699258A4 (en) * | 2011-04-15 | 2014-10-29 | Us Sec Dep Of Health And Human Services | TRANSFER OF AAV-MEDIATED CTLA-4 GENE TO TREAT THE SJÖGREN SYNDROME |
EP2709653B1 (en) | 2011-04-20 | 2017-11-22 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity |
TWI527590B (zh) * | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Fgf-18之凍乾調配物 |
MX360706B (es) | 2011-10-07 | 2018-11-14 | Takeda Pharmaceuticals Co | Compuestos de 1-arilcarbonil-4-oxi-piperidina utiles para el tratamiento de enfermedades neurodegenerativas. |
JP6163158B2 (ja) | 2011-10-13 | 2017-07-12 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Cd40lに拮抗する抗体ポリペプチド |
US10493151B2 (en) | 2011-10-18 | 2019-12-03 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with sodium chloride |
WO2013059406A1 (en) | 2011-10-18 | 2013-04-25 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with metal ions |
SI2867251T1 (sl) | 2012-06-29 | 2019-12-31 | Bristol-Myers Squibb Company | Postopki za zmanjšanje agregacije glikoproteina |
EP2869903B1 (en) * | 2012-07-06 | 2018-11-28 | 3-D Matrix Ltd. | Fill-finish process for peptide solutions |
EP2869817A4 (en) | 2012-07-09 | 2016-04-06 | Coherus Biosciences Inc | STABLE AQUEOUS FORMULATIONS OF ETANERCEPT |
ES2729561T3 (es) | 2012-08-31 | 2019-11-04 | Us Health | Transferencia del gen acuaporina mediada por un virus adenoasociado (aav) para el tratamiento del síndrome de Sjögren |
PE20191815A1 (es) | 2012-09-07 | 2019-12-27 | Coherus Biosciences Inc | Formulaciones acuosas estables de adalimumab |
BR112015005161A2 (pt) | 2012-09-11 | 2017-07-04 | Coherus Biosciences Inc | etanercepte corretamente dobrado em alta pureza e excelente rendimento |
US10450361B2 (en) | 2013-03-15 | 2019-10-22 | Momenta Pharmaceuticals, Inc. | Methods related to CTLA4-Fc fusion proteins |
EP2996772B1 (en) | 2013-05-13 | 2018-12-19 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
CN103385852B (zh) * | 2013-08-06 | 2015-03-11 | 南京正大天晴制药有限公司 | 一种盐酸法舒地尔注射液及其制备方法 |
EP3043774B1 (en) | 2013-09-11 | 2020-11-04 | Eagle Biologics, Inc. | Liquid protein formulations containing ionic liquids |
EP3058084A4 (en) | 2013-10-16 | 2017-07-05 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
JP6684719B2 (ja) | 2014-03-10 | 2020-04-22 | 株式会社スリー・ディー・マトリックス | ペプチド組成物の滅菌および濾過 |
WO2015138514A1 (en) | 2014-03-10 | 2015-09-17 | 3-D Matrix, Ltd. | Self-assembling peptide compositions |
MX2016011102A (es) | 2014-03-19 | 2017-01-26 | Bristol Myers Squibb Co | Metodos para tratar rechazo al trasplante usando un anticuerpo de dominio dirigido contra cd40l. |
CN106456784A (zh) * | 2014-04-16 | 2017-02-22 | 拜康有限公司 | 包含摩尔过量的山梨醇的稳定蛋白质制剂 |
AU2015249656A1 (en) | 2014-04-25 | 2016-11-03 | Bristol-Myers Squibb Company | Use of CTLA4 compound for achieving drug-free remission in subjects with early RA |
WO2015196091A1 (en) * | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
EP3157942B1 (en) | 2014-06-23 | 2020-06-17 | Novartis AG | Site specific protein modifications |
EP3200804A4 (en) | 2014-10-01 | 2018-04-18 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
MA41580A (fr) | 2015-01-23 | 2017-11-29 | Novartis Ag | Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée |
MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
KR20180051543A (ko) * | 2015-09-11 | 2018-05-16 | 다우 글로벌 테크놀로지스 엘엘씨 | 단백질 및 폴리알콕시 지방 화합물을 포함하는 조성물 |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
ES2823279T3 (es) | 2015-12-07 | 2021-05-06 | Merck Patent Gmbh | Formulación farmacéutica acuosa que comprende el anticuerpo anti-PD-1 Avelumab |
WO2017109706A1 (en) | 2015-12-22 | 2017-06-29 | Novartis Ag | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
WO2017120092A1 (en) | 2016-01-06 | 2017-07-13 | 3-D Matrix, Ltd. | Combination compositions |
EP3192805A1 (en) | 2016-01-15 | 2017-07-19 | Humanitas Mirasole S.p.A. | Inhibitors of t cell activation or stimulation and uses thereof |
US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
EA201991383A1 (ru) | 2016-12-07 | 2019-12-30 | Эйдженус Инк. | Антитела против ctla-4 и способы их применения |
WO2018217918A2 (en) | 2017-05-24 | 2018-11-29 | Als Therapy Development Institute | Therapeutic anti-cd40 ligand antibodies |
IL307483A (en) | 2017-12-22 | 2023-12-01 | Novartis Ag | Methods for treating metabolic disorders with FGF21 variants |
CN108014338A (zh) * | 2018-01-22 | 2018-05-11 | 安徽未名生物医药有限公司 | 一种注射用巴利昔单抗冻干粉针及其制备方法 |
BR112020023860A2 (pt) * | 2018-05-25 | 2021-04-13 | Dr. Reddy's Laboratories Ltd. | Formulação estável de proteína de fusão, e, métodos para obter uma formulação estável e para aumentar a estabilidade de proteína de fusão |
SG11202011354VA (en) * | 2018-05-25 | 2020-12-30 | Dr Reddys Laboratories Ltd | Ctla4-ig fusion protein formulation |
EP3813791A2 (en) * | 2018-06-26 | 2021-05-05 | Lupin Limited | Stable lyophilized dosage form of protein |
CN110876269B (zh) * | 2018-06-29 | 2021-07-30 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
WO2020109978A1 (en) | 2018-11-26 | 2020-06-04 | Novartis Ag | Lpl-gpihbp1 fusion polypeptides |
AU2020208909A1 (en) | 2019-01-15 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mutated interleukin-34 (IL-34) polypeptides and uses thereof in therapy |
EP3914282A1 (en) | 2019-01-25 | 2021-12-01 | Ospedale San Raffaele S.r.l. | Inhibitor of dux4 and uses thereof |
JP7044822B2 (ja) | 2019-09-09 | 2022-03-30 | 株式会社タクマ | 燃焼制御システム、燃焼制御方法、情報処理装置、プログラムおよび記録媒体 |
GB201913697D0 (en) | 2019-09-23 | 2019-11-06 | King S College London | DAP10/DAP12 fusion polypeptides |
GB202003277D0 (en) | 2020-03-06 | 2020-04-22 | King S College London | Therapeutic agents |
GB202007655D0 (en) | 2020-05-22 | 2020-07-08 | King S College London | Chimeric nkg2d protein |
US20240083970A1 (en) * | 2021-02-01 | 2024-03-14 | Dr. Reddy’S Laboratories Limited | Compositions comprising fusion protein and analytical attributes thereof |
WO2022200442A1 (en) | 2021-03-23 | 2022-09-29 | King's College London | Compositions comprising nkg2d, cxcr2, and dap10/dap12 fusion polypeptides and methods of use thereof |
CN113925963B (zh) * | 2021-10-15 | 2023-08-11 | 江苏太平洋美诺克生物药业股份有限公司 | 一种稳定的包含抗cd147单克隆抗体的药物制剂 |
GB202214120D0 (en) | 2022-09-27 | 2022-11-09 | King S College London | Compositions comprising NKG2D, CXCR2, and DAP10/DAP12 fusion polypeptides and methods of use thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3698721B2 (ja) * | 1993-02-23 | 2005-09-21 | ジェネンテク・インコーポレイテッド | 有機溶媒を用いて処理したポリペプチドの賦形剤安定化 |
DE4405426A1 (de) * | 1994-02-21 | 1995-08-24 | Boehringer Mannheim Gmbh | Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
CA2226575C (en) * | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
WO2003005465A1 (en) | 2001-04-25 | 2003-01-16 | Quallion, Llc | Rechargeable lithium battery for tolerating discharge to zero volts |
US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
US7183376B2 (en) * | 2000-06-23 | 2007-02-27 | Maxygen, Inc. | Variant B7 co-stimulatory molecules |
TWI322153B (en) * | 2000-07-03 | 2010-03-21 | Bristol Myers Squibb Co | Methods for treating rheumatic diseases using a soluble ctla4 molecule |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
AU2002243905B2 (en) * | 2001-01-26 | 2007-11-08 | Emory University | Methods of inducing organ transplant tolerance and correcting hemoglobinopathies |
DE60237841D1 (de) * | 2001-11-13 | 2010-11-11 | Genentech Inc | Zusammensetzungen basierend auf APO2-Ligand/ TRAIL und ihre Verwendung |
DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
DE10204792A1 (de) | 2002-02-06 | 2003-08-14 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Immuncytokine |
KR101080021B1 (ko) | 2002-02-14 | 2011-11-04 | 추가이 세이야쿠 가부시키가이샤 | 항체함유 용액제제 |
ES2354610T5 (es) | 2002-12-23 | 2020-09-14 | Bristol Myers Squibb Co | Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína |
WO2004058800A2 (en) * | 2002-12-23 | 2004-07-15 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
RU2332986C2 (ru) | 2003-04-04 | 2008-09-10 | Дженентек, Инк. | Высококонцентрированные композиции антител и белков |
BRPI0413326A (pt) * | 2003-08-04 | 2006-10-10 | Bristol Myers Squibb Co | métodos para tratar doença cardiovasculares empregando-se uma molécula ctla4 solúvel |
JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
AU2006295340B2 (en) * | 2005-08-05 | 2010-11-11 | Amgen Inc. | Stable aqueous protein or antibody pharmaceutical formulations and their preparation |
CN101822820A (zh) * | 2005-12-20 | 2010-09-08 | 布里斯托尔—迈尔斯斯奎布公司 | 稳定蛋白质制剂 |
-
2006
- 2006-12-19 CN CN200910139825A patent/CN101822820A/zh active Pending
- 2006-12-19 CA CA2634547A patent/CA2634547C/en active Active
- 2006-12-19 NZ NZ569108A patent/NZ569108A/en unknown
- 2006-12-19 AR ARP060105626A patent/AR058567A1/es not_active Application Discontinuation
- 2006-12-19 PT PT68466838T patent/PT1962886E/pt unknown
- 2006-12-19 PL PL06846683.8T patent/PL1962886T6/pl unknown
- 2006-12-19 ES ES06846683T patent/ES2436616T5/es active Active
- 2006-12-19 RS RS20130553A patent/RS53127B2/sr unknown
- 2006-12-19 EP EP06846683.8A patent/EP1962886B2/en active Active
- 2006-12-19 HR HRP20131196TT patent/HRP20131196T4/hr unknown
- 2006-12-19 TW TW098139141A patent/TW201008595A/zh unknown
- 2006-12-19 EA EA200801570A patent/EA014232B1/ru active Protection Beyond IP Right Term
- 2006-12-19 PE PE2006001649A patent/PE20071063A1/es active IP Right Grant
- 2006-12-19 AU AU2006330593A patent/AU2006330593B2/en active Active
- 2006-12-19 DK DK06846683.8T patent/DK1962886T4/da active
- 2006-12-19 CN CN2006800530514A patent/CN101378773B/zh active Active
- 2006-12-19 WO PCT/US2006/062297 patent/WO2007076354A2/en active Application Filing
- 2006-12-19 SG SG200904148-4A patent/SG153832A1/en unknown
- 2006-12-19 TW TW098139142A patent/TWI393575B/zh active
- 2006-12-19 CN CNA2009101398246A patent/CN101584858A/zh active Pending
- 2006-12-19 BR BRPI0622256-0A patent/BRPI0622256A2/pt not_active Application Discontinuation
- 2006-12-19 KR KR1020087017544A patent/KR101378194B1/ko active IP Right Grant
- 2006-12-19 US US12/086,876 patent/US8476239B2/en active Active
- 2006-12-19 TW TW095147647A patent/TW200738261A/zh unknown
- 2006-12-19 JP JP2008547721A patent/JP5247467B2/ja active Active
- 2006-12-19 NO NO20082628A patent/NO347247B1/no unknown
-
2008
- 2008-06-12 IL IL192104A patent/IL192104A/en active IP Right Grant
- 2008-09-12 HK HK08110158.9A patent/HK1114568A1/xx unknown
-
2010
- 2010-07-30 CL CL2010000816A patent/CL2010000816A1/es unknown
-
2011
- 2011-06-27 JP JP2011141983A patent/JP5538309B2/ja active Active
-
2014
- 2014-09-04 AR ARP140103315A patent/AR097561A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20071063A1 (es) | Formulaciones de proteinas estables | |
US20180371448A1 (en) | Modifications of peptide compositions to increase stability and delivery efficiency | |
AR117403A2 (es) | Formulaciones de anticuerpos | |
ATE252601T1 (de) | Lang wirkende insulinotrope peptide | |
EP1626055A3 (en) | Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system | |
UA89798C2 (ru) | Стабильный водный препарат антитела в гистидинацетатном буфере | |
NZ592510A (en) | HLA-A*1101-restricted WTI peptide and pharmaceutical composition comprising the same | |
HRP20110242T1 (hr) | Formulacija s fuzijskim proteinom glp-1-fc | |
CA2485217A1 (en) | Insulin-associated peptides with effects on cerebral health | |
NZ593311A (en) | Albumin binding peptide-mediated disease targeting | |
WO2006050930A3 (en) | Conjugates with enhanced cell uptake activity | |
CR7938A (es) | Formulaciones parenterales de peptidos para el tratamiento de lupus eritematoso sistemico | |
PE20120425A1 (es) | Metodos y composiciones en base a la proteina tipo 2 de la toxina shiga | |
RU2010111139A (ru) | Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства | |
RU97105374A (ru) | Модифицированные белки | |
UA93365C2 (ru) | Инъекционная форма диклофенака и его фармацевтически приемлемых солей (варианты) и способ его приготовления (варианты) | |
WO2004112838A3 (en) | Codrugs of diclofenac | |
DE60031259D1 (de) | Nährstoffe aus sojabohnenprotein | |
BR0213821A (pt) | Conjugados de polìmero/peptìdeo timosina alfa 1 | |
WO2000070665A3 (en) | Long lasting anti-angiogenic peptides | |
JP2005506276A5 (es) | ||
TW200505943A (en) | Polypeptide | |
AR014884A1 (es) | Uso de un conjugado de angiotensina inmunogenico y composicion farmaceutica | |
AU3739500A (en) | Protease resistant flint analogs | |
MXPA01008349A (es) | Formulacion farmaceutica estable para la administracion intravenosa o intramuscular de octreotide. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |